Two recent major randomized clinical trials [5, 6] have demonstrated that PSA screening contains a significant risk of overdiagnosis for prostate cancer where it is estimated that 50 % of screened men are diagnosed with prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.